<bill session="118" type="s" number="146" updated="2025-04-21T12:24:17Z">
  <state datetime="2023-01-30">REFERRED</state>
  <status>
    <introduced datetime="2023-01-30"/>
  </status>
  <introduced datetime="2023-01-30"/>
  <titles>
    <title type="display">Cap Insulin Prices Act</title>
    <title type="official" as="introduced">A bill to reduce the price of insulin for patients.</title>
    <title type="short" as="introduced">Cap Insulin Prices Act</title>
  </titles>
  <sponsor bioguide_id="H001089"/>
  <cosponsors>
    <cosponsor bioguide_id="W000790" joined="2023-11-07"/>
  </cosponsors>
  <actions>
    <action datetime="2023-01-30">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2023-01-30" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
    <action datetime="2024-06-12">
      <text>Committee on Banking, Housing, and Urban Affairs. Hearings held.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSBK" name="Senate Banking, Housing, and Urban Affairs" subcommittee="" activity="Hearings By (Full Committee)"/>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referred To"/>
  </committees>
  <relatedbills>
    <bill session="118" type="h" number="1488" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug therapy"/>
    <term name="Employee benefits and pensions"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2023-05-01T20:08:38Z" status="Introduced in Senate">Cap Insulin Prices Act

This bill reduces cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.

Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $25 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2024.

The bill caps cost-sharing under the Medicare prescription drug benefit for a month's supply insulin products at $25 beginning in 2024. The current cap on insulin products under Medicare is $35 per month.</summary>
</bill>
